UroGen's ZUSDURI inflects: 73% QoQ jump, a patent wall to 2044 — and the 'reverse halo' that isn't
With repeat prescribers nearly doubling and community mix passing 55%, the launch has stepped ahead of linear growth; the franchise now has runway to 2044.
URGN · Earnings Call · 2026-08-05
Inflection at last
UroGen has finally delivered the quarter its long-suffering shareholders have been waiting for. ZUSDURI, the first FDA-approved nonsurgical option for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, generated $50.4M in net product revenue in Q2 — up 73% quarter-over-quarter and, by management's own admission, ahead of the linear ramp they had modelled. The market noticed: the stock has rallied roughly 117% over the trailing 90 trading days, to within 7% of its recent peak.It's not just top-line revenue. Activated accounts climbed from 972 to 1,444; unique prescribers nearly doubled to 452; and repeat prescribers — the metric management calls its strongest indicator of long-term franchise health — nearly doubled to 204, now ~45% of writers. The repeat utilization story is the crux of the thesis: physicians are converting first-time users into a routine part of their bladder-cancer workflow. Management also cited improving patient-enrollment-to-treatment conversion, moving toward JELMYTO's 2- to 3-week cadence.ZUSDURI generated $50.4 million in net product revenue during the second quarter, representing a 73% growth over the first quarter. More importantly, the commercial trends underlying that growth continue to strengthen.
Commercial readiness, scaled to the community
Perhaps the most under-appreciated data point is channel mix. Community practices now account for ~55% of utilization, versus 45% at hospitals — and management estimates ~70% of the addressable market lives there. That mix shift is a direct result of the permanent J-code (effective January 2026) removing the billing friction that had kept community urologists on the sidelines; management says reimbursement is no longer "a meaningful constraint to adoption." The durability data is the second pillar. The Phase III ENVISION readout at ~3 years showed a Kaplan-Meier estimate of 64.5% disease-free probability at 36 months among complete responders, with the median duration of response still not reached at a median follow-up of 35.5 months — achieved with no maintenance therapy. On the Q&A, Liz Barrett leaned into that benchmark: “I'd like to challenge anyone to meet or beat those -- that type of data out in the marketplace.” — Elizabeth Barrett, Chief Executive Officer · 2026-08-05The franchise is now a long-duration asset
Three strategic moves this quarter transformed UroGen from a single-product launch into a multi-asset franchise with a lengthened runway: - **The Teva settlement** resolved JELMYTO patent litigation, removing a key overhang on that product's commercial runway. - **A new method-of-treatment patent** covering both ZUSDURI and UGN-103, expected to protect into July 2044. - **An accelerated investment posture**: full-year operating expense guidance raised to $260–270M, with incremental spend at HCP education, patient awareness, and early-stage pipeline (UGN-103 high-grade trial, UGN-501 Phase I with RTGel). Despite the spend increase, CFO Chris Degnan reiterated confidence in reaching profitability with existing capital. “We view these as disciplined high-return investments that have the potential to strengthen the long-term profile of the business. Importantly, this increased investment does not change our confidence to reach profitability with our existing capital resources.” — Christopher Degnan, Chief Financial Officer · 2026-08-05 The margin structure supports that claim: revenue is compounding while gross margin prints at 91.9% and R&D spend is actually down year-over-year. On the prior call (May 2026), management framed the launch against ANKTIVA's post-J-code analog: “when we looked at the first 6 months with the permanent J-code, they saw a 220% step-up in their revenue... we're tracking ahead of that analog.” — Christopher Degnan, Chief Financial Officer · 2026-05-06What's not happening: the reverse halo
Investors have repeatedly asked whether ZUSDURI's success would pull JELMYTO (upper-tract urothelial cancer) along. Management's answer is refreshingly honest: not yet.JELMYTO grew only modestly ($22.0M vs $21.7M QoQ), within the guided $97–101M full-year band. Liz attributes the lack of spillover partly to competitor trials "taking patients" — including UroGen's own UGN-104 study — that otherwise might have been JELMYTO patients. The flip side: ZUSDURI is bringing new doctors into the franchise who later write JELMYTO, so the sequential leverage may still materialize. It's a useful reminder that this is still very early: as noted on the May call, the company's prescriber universe target is 8,500, against roughly 452 unique writers today — “we've only got 300 unique prescribers” — Elizabeth Barrett, Chief Executive Officer · 2026-05-06 then. Management was also careful to damp expectations of a new run-rate: “we do not expect to see that [acceleration], particularly in Q3” — Elizabeth Barrett, Chief Executive Officer · 2026-08-05 — a signal that the 73% QoQ print was a step-change, not an exponential curve.Look, to answer your question, no, we have not seen the -- what I call a reverse halo on JELMYTO... do I hope that we will? Yes, absolutely.